Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 9605080 Antibodies against CD73

Patent 9605080 was granted and assigned to Bristol-Myers Squibb on March, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Date Filed
January 13, 2016
Date of Patent
March 28, 2017
Patent Applicant
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent Application Number
14994828
Patent Citations Received
‌
US Patent 11884665 Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
0
‌
US Patent 12060433 CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
0
‌
US Patent 11999740 Fused pyrazine derivatives as A2A / A2B inhibitors
0
‌
US Patent 12018089 Anti-CD73 antibodies and uses thereof
0
‌
US Patent 11873304 Fused pyrimidine derivatives as A2A/A2B inhibitors
0
Patent Inventor Names
Maria N. Jure-Kunkel
0
Martin J. Corbett
0
Ming Lei
0
Mohan Srinivasan
0
Nils Lonberg
0
Pingping Zhang
0
Richard Huang
0
Sandra V. Hatcher
0
John S. Sack
0
Aaron P. Yamniuk
0
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9605080
Patent Primary Examiner
‌
Robert Landsman

Find more entities like US Patent 9605080 Antibodies against CD73

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo